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CHAPTER 9
ADULT ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Laura E. Knouse, M.A. and Steven A. Safren, Ph.D.

Attention-Deficit Hyperactivity Disorder (ADHD) is a developmental disorder
characterized by symptoms of inattention, hyperactivity, and impulsivity that causes
significant impairment in multiple domains of functioning[1]. Nearly two decades of research
support the idea that ADHD continues to affect a substantial proportion of patients into
adulthood [2] [3]. A recent population-based survey estimated the prevalence of ADHD in
the adult population at 4.4%, which is consistent with previous estimates [4] and adults are
now specifically seeking services for ADHD in mental health care settings.
While the validity of ADHD in adulthood has been empirically established, evidence
concerning the accurate assessment and appropriate treatment of the disorder in adults lags
behind the knowledge base for children. Even for an experienced clinician, adult ADHD is
often difficult to diagnose. Self-report rating scales can generate useful information to guide
clinical decision-making throughout the process of assessment and treatment. Ratings
collected over time can be a source of data to guide treatment-related decision-making and
improve communication between provider and patient.
Rating scales can play three distinct roles in clinical work with adults with ADHD:
(1) rating scales can be used as a general screening for patients in a variety of settings,
with the goal of identifying adults who might require more comprehensive evaluation and
follow-up.
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(2) rating scales can be used as part of an evaluation to obtain data pertaining to several
of the diagnostic criteria for ADHD.
(3) rating scales can be used to repeatedly assess the effects of treatment on symptom
severity.
In this chapter, we focus primarily on the use of rating scales in the first and third roles -- screening and tracking treatment-related change --- because a comprehensive discussion of
the role of rating scales in a multi-faceted adult ADHD assessment is beyond the scope of
this chapter. We wish to emphasize that the establishment of a diagnosis of ADHD in adults
cannot be accomplished using rating scales alone (see also “Conclusions” at the end of this
chapter.) However, later in this chapter we briefly address how evidence for Diagnostic and
Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV) [1] criteria could be
gleaned from a rating scale.

SUGGESTED RATING SCALES FOR ADHD
Current Symptoms Scale (CSS) [Barkley & Murphy, 2006][5]
Adult ADHD Self-Report Scale (ASRS) [Kessler et al., 2005][6]

Current Symptoms Scale (CSS)1
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The CSS is protected by copyright and therefore is not reproduced here. It is available in: Attention-Deficit
Hyperactivity Disorder: A Clinical Workbook – 3rd Edition (Barkley & Murphy, 2006). The workbook also includes
self-report scales assessing childhood symptoms retrospectively. Other-report forms for both current and past
symptoms can be used to collect collateral information for assessment and treatment tracking. Normative data tables
are also provided along with instructions on how to administer, score, and interpret results. Scales assessing other
areas including medication side effects, risky driving behavior, and work performance are also provided, as are
forms for use with children. Barkley & Murphy encourage clinicians to photocopy and use these forms in their
practice.
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Our research program at Massachusetts General Hospital develops and tests cognitivebehavioral interventions for adults who, despite medication treatment for their ADHD, continue
to display residual symptoms. We use the self-report Current Symptoms Scale [5] both to assess
treatment-related change in symptoms over time and as part of our baseline evaluations, because
of its widespread use in research and clinical settings and the close correspondence of its items to
DSM-IV criterion symptoms.
The CSS consists of the 18 DSM-IV inattentive and hyperactive-impulsive symptom items,
worded in the first person and with some wording modified to fit adults (e.g. “playing” changed
to “engaging in leisure activities”). Patients begin by rating their behavior over the past 6 months
with respect to each item on a 4-point Likert scale (Never or Rarely, Sometimes, Often, or Very
Often) scored 0-3. Thus, severity scores on the CSS can range from 0-54 across all symptoms.
Next, they indicate the age the onset for endorsed symptoms. Finally they rate how often these
symptoms have interfered with functioning in ten areas of life.
Application of Scale: The CSS is administered throughout our treatment outcome
studies. Patients first complete the measure at their baseline assessment to establish an initial
level of symptom severity. Importantly, the CSS is only one measure in a large battery of
baseline assessments – both self-report and clinician-administered—that we use in establishing
the ADHD diagnosis and assessing its associated features. We use total scores on the CSS as
baseline data. Separate totals from inattentive versus hyperactive-impulsive symptom clusters are
useful in follow-up analyses of our data. The CSS is also completed at post-treatment and at 6and 12-month follow-up assessments.
During our treatment studies, the CSS is used to track symptoms on a weekly basis.
Patients are instructed to complete the 18 DSM-IV items of the scale at the beginning of each
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treatment session and to try to rate the past week only. When the patient finishes the scale, his or
her therapist totals the score and also looks over each item individually. They briefly discuss
which items appear to be improving and which are still problematic for the patient. Importantly,
the therapist directs the patient to talk about which skills the patient used successfully over the
past week and how this may have impacted his or her ratings. This is important because we have
found that patients with ADHD sometimes complete the scale with a “trait-like” attitude toward
their ratings rather than considering behavioral changes that may have occurred more recently.
Each week, the CSS helps us to track changes in symptoms and also serves as an important
forum for patients and therapists to discuss how treatment is progressing. When patients are able
to see even small gains as a result of their work in treatment, it can sustain their motivation to
continue to practice their new skills until the skills become less effortful.
The CSS could also be useful to clinicians as part of a comprehensive evaluation of
ADHD in adults. The scale yields data for DSM-IV Criterion A (symptom counts, developmental
deviance via norms), Criterion B (symptom onset), and Criterion C (impairment across settings).
Barkley and Murphy (2006) suggest that clinicians can score items rated as “often” or more as an
indicator of DSM-IV symptom counts, although we have heard of using items rated as
“sometimes” to be counted as a half symptom. Accordingly, a person would need two of these
within the domain (inattention or hyperactivity-impulsivity) to “count” toward the 6-symptom
criterion for diagnosis. Published deviance cutoffs for the scale enable the clinician to gauge
symptom deviance compared to a general population sample (Criterion A). The scale collects
information about symptom onset (Criterion B) and information about functional impairment
across domains (Criterion C). However, during our evaluations we augment rating scale data
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using structured diagnostic interviews, clinician ratings, and other self-report scales (e.g. quality
of life, symptoms of other disorders).
Scoring Key: In our work, we have primarily used a simple sum of patient’s self-report
symptom ratings of the 18 DSM-IV ADHD items as an indication for ADHD symptom severity
(0-54 range). The clinician can also obtain totals for inattentive versus hyperactive-impulsive
symptoms separately – odd numbered items for inattentive and even numbered items for
hyperactive-impulsive symptoms with a range of 0-27 for each symptom cluster. See above
section for how the CSS could be used to obtain symptom counts.
Cutoff Scores: The clinical workbook in which the CSS is published [5] contains agebased deviance thresholds (1.5 standard deviations above the mean) for inattentive symptoms,
hyperactive-impulsive symptoms, and total ADHD symptoms. These can be used as clinical
cutoff scores.
Clinically Significant Change: We compare total scores on this measure at follow-up to
those obtained at the baseline assessment. Medication treatment trials often consider a 30%
reduction in scores from baseline a response to treatment [7]. While the symptom ratings of a
clinician blinded to treatment condition serve as our primary outcome measure in the research
setting, we believe that self-report ratings capture aspects of treatment-related change that are not
reflected in the ratings of others. For example, the patient may be in the best position to
sensitively rate changes in outcomes such as improvements in sustained attention. Thus, selfreport data collected via rating scales continues to be an important part of the measurement of
change in our research and clinical work.
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Adult ADHD Self-Report Scale (ASRS)
The ASRS (ASRS-v1.1; [6][8]) is reproduced at the end of this chapter. It is an 18-item
self-report scale developed by the World Health Organization as a screening tool for ADHD in
adults that contains items similar to those of the CSS. There are two versions of the ASRS: a
short screening version of six items (contained in Part A of the scale) and a full 18-item version
containing content from all DSM-IV symptoms (Parts A and B). The ASRS has a growing body
of literature supporting its reliability and validity, and is available online at no cost, with links to
various language versions and background data available at
http://www.hcp.med.harvard.edu/ncs/asrs.php .The full scale is available in English, Chinese
(traditional), Danish, French, Hebrew, Norwegian, and Swedish. The 6-question screening
version, Part A of the scale reproduced here, is also available in Chinese (Mandarin), Dutch,
German, Japanese, Portuguese, Russian, and Spanish (both for use in Mexico/U.S. and Spain).
Note, however, that no research on the properties of these translated instruments has been
conducted.
The ASRS was developed for use in World Health Organization (WHO) Mental Health
Initiative surveys, designed to collect data from over 200,000 respondents in 28 countries.
Kessler et al. [6] developed this new self-report measure covering all 18 DSM-IV symptoms with
items re-worded to be more appropriate for adults. For each item of the ASRS, patients rate the
frequency with which each symptom occurred over the past six months on a 0-4 scale with points
labeled as Never, Rarely, Sometimes, Often, or Very Often. The scale was focused on frequency
of symptoms rather than severity to make scale instructions easier for participants to understand.
Application of the Scale: The complete ASRS-v.1.1 and its published instructions are
reprinted on pages XX and are copyrighted by the World Health Organization. We describe
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using the ASRS-v1.1 for two purposes: as a screening tool and as a way to track changes in adult
ADHD symptoms in response to treatment. As a screening tool, the clinician should follow the
scale instructions (page XX; see also updated information on scoring of Part A in Scoring Key
and Cutoff Points section) and refer patients who exceed these cutpoints for further evaluation
for possible adult ADHD. Clinicians should keep in mind, however, that this screening threshold
still fails to identify a substantial portion (about 35%) of adults who meet criteria for adult
ADHD using diagnostic interviews [6].. Therefore, following up with individual patients who
display elevated scores on this measure (but who do not meet or exceed the threshold) may be
warranted.
Based on our experience with the 18 DSM-IV items of the Current Symptom Scale, we
suggest that the ASRS could be used as often as weekly to track treatment-related changes in
adult ADHD symptoms. Recent adult ADHD medication trials have used symptom-based selfreport measures and these scales appear to be sensitive to treatment-related change
[9][10][11][12]. Self-reports are often used in conjunction with clinician ratings in medication
studies. Importantly, the clinician-rated version of the ASRS, the AISRS, has been sensitive to
treatment-related change in three recent studies [13][14][15]. While far fewer studies exist on
tracking the efficacy of psychosocial treatment in treating adult ADHD, our own work using the
CSS supports the sensitivity of this type of measure. For example, our group found that adults
receiving a cognitive-behavioral treatment package reported, on average, a 50% reduction in
total scores on the CSS from baseline assessment to post-treatment [16]. Solanto and collegues
[17] recently found that their Meta-Cognitive Therapy group treatment was associated with
significant reductions on the DSM-IV-based inattentive items of the self-report Conners' Adult
ADHD Rating Scale (CAARS;[18]). Because items on the ASRSv1.1 also parallel the DSM-IV
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symptoms, total scores on this measure are likely to be sensitive to treatment-related changes. In
addition, the expanded range of total scores on this measure (0-72 vs. 0-54) and its increased face
validity for ADHD symptoms in adults may increase its sensitivity to change, but this possibility
has not yet been investigated empirically.
Clinicians can administer the ASRSv1.1 at their initial evaluation visit with a patient to
establish a baseline level of total symptom scores on the measure. At each subsequent treatment
session or follow-up visit, the patient should complete the measure with respect to the time
period since the last session prior to his or her discussion with the clinician during that session.
(This will avoid biasing the patient’s ratings in the direction of the clinician’s impressions.) We
find it important to remind the patient frequently regarding the time-frame of the symptoms to
maximize the chances that his or her ratings reflect behavior during the previous week rather
than his or her behavior in general. The clinician should then total the patient’s score on the
measure and keep a record. For example, a computerized spreadsheet containing a record for
each patient’s weekly measures is an excellent way to organize and track scores. Later, these
scores can be easily plotted on a chart and used in discussions of treatment effectiveness. During
a particular appointment, the clinician should note the pattern of change from the previous visit
and discuss with the patient whether this pattern reflects the patient’s subjective impression of
changes in symptoms. If the treatment in question is a psychosocial treatment, the clinician can
note individual symptoms that have improved and those that continue to be problematic and use
this in a discussion of which skills and strategies the patient has been able to implement
successfully. This process can help both patient and clinician to more efficiently direct their time
and efforts toward the most severe symptoms.
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The screening thresholds previously mentioned could also be used targets below which it
is less likely that the patient would meet criteria for adult ADHD upon clinical interview.
Importantly, symptom scales should always be used to track progress in conjunction with
evidence of improvement in functional domains based on the patient’s report and other measures.
In addition, rating scales appropriate for tracking symptoms of comorbid disorders (e.g.,
depression or anxiety) should also be administered during treatment if a patient’s evaluation
indicates that these symptoms are prominent.

Copy of Rating Scale: (insert here)

Scoring Key and Cutoff Points: Kessler et al. [6] identified thresholds for each item with
maximum concordance with interview results. For 7 items, a rating of “Sometimes” (score of 2)
best differentiated a positive symptom on the interview and for the remaining 11 items a rating of
“Often” or higher (score of 3) was most appropriate. These thresholds correspond to the gray
boxes on the form reprinted here. While the authors point out that a clinician could use a DSM-IV
threshold of 6+ symptoms on either list to define diagnosis, they tested several scoring methods
to determine which method best predicted diagnosis.
Following the recommendations of the scale’s authors when using the entire scale (parts
A and B), the clinician should count up the number of items the patient endorses that fall in the
gray shaded boxes. If this symptom count is 9 or greater, the patient may need to be referred for
further evaluation. Using only the 6-item screening scale contained in Part A, the authors now
recommend adding up the total score (of items rated 0-4) rather than counting responses in the
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gray boxes as suggested in the instructions and following up with patients whose total scores are
14 or higher [19].
Reliability and Validity: A subsample of 154 participants age 18-44 in the National
Comorbidity Survey Replication (NCSR) was the test sample for the ASRS. Participants in four
representative subgroups (no childhood ADHD, some symptoms in childhood, diagnosis in
childhood but deny current symptoms, diagnosis in childhood and endorse current symptoms)
completed a structured, clinician-administered interview of current ADHD symptoms and the
ASRS. The authors found a significant correlation of .43 between total scores on the ASRS (0-72)
and current clinical symptom severity and suggest that this finding may support the use of the
ASRS in charting clinical improvement among treatment cases. Providing further evidence for
the use of this scale in the clinical population, data from 60 adult ADHD clinic patients who
completed the ASRS and clinician interview were analyzed to assess concurrent validity and
internal consistency [20]. Internal consistency for the ASRS (alpha = .88) was very good.
Interclass correlation coefficients between the ASRS and clinician-administered interview were
high (.84) with significant Kappa coefficients for each item.
More recently, data using the 6-item screening version of the ASRS were collected from a
representative sample of 668 health plan members to assess its psychometric properties and to
cross-validate this brief screening scale [19]. Internal consistency for continuous scores ranged
from .63-.72 and test-retest reliability ranged from .58 - .77. Note, however, that these values
apply only to the 6-item screener and not the full 18-item scale.
Clinically Significant Change: Changes in total scores on the ASRSv1.1 or any other
symptom-based measure of adult ADHD can provide information to aid in decision-making
about treatment course. A 30% reduction in overall scale scores can be used as a guideline for
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treatment response. This threshold is often employed in ADHD medication treatment studies [7])
and was used in a medication treatment study that employed the clinician-report version of the
ASRS [14]. However, patient and clinician may decide to set a lower (or higher) threshold of
symptoms severity as the goal of treatment, depending on a patient’s level of functioning and
baseline severity.
Comment on Symptom-Based Scales: Brief comment on the strengths and weaknesses of
symptom-based scales such as the ASRS in warranted. A growing body of literature supports the
ASRS, particularly as a screening tool. Its item wording appears to be face valid and appropriate
for tapping the expression of DSM-IV ADHD symptoms in adults. The scale is widely available
and has numerous non-English translations available. There is evidence that similarlyconstructed scales are sensitive to change in medication and psychosocial treatment studies. The
weaknesses of symptom-based scales highlight the need to augment the assessment and
treatment process with other measures and procedures. The ASRS and some other adult rating
scales do not provide information on childhood symptoms, which is critical to making an ADHD
diagnosis. Symptom-based scales do not generate corroborating evidence from others of either
current or childhood symptoms. The scale assesses only the frequency—not the functional
impact—of symptoms. For these reasons, it is critical that scales like the ASRSv1.1 be used for
screening or tracking symptom frequency and not used as the sole basis of clinical diagnosis. As
discussed previously, rating scales are only one tool in a comprehensive evaluation of adult
ADHD that should also include diagnostic interview, detailed history, evidence of functional
impact of ADHD, other report of symptoms, review of documentation, and thorough assessment
of comorbid conditions.
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OTHER SCALES AVAILABLE FOR THIS DISORDER
Though a comprehensive review of rating scales available for adults with ADHD is
beyond the scope of this chapter, we briefly mention one other widely available set of rating
scales that a clinician working with this population might consider--Conners’ Adult ADHD
Rating Scales (CAARS; [18]). Detailed reviews of a much wider range of adult ADHD rating
scales are available [21][22]. Notably, the CAARS can be used to partially bolster some of the
weaknesses of a simpler scale like the ASRS v1.1.
Involving a wide normative base and strong psychometric properties, the CAARS are selfand other-report measures of current adult ADHD symptoms. The CAARS items were derived
from a pool of 93 items thought to be related to the manifestation of ADHD in adults and
carefully selected based on exploratory factor analysis [23]. The final 66-item self-report scale
includes the DSM-IV based items with adult-appropriate wording and non-DSM items loading
on 4 dimensions: inattention/memory problems, hyperactivity/restlessness, impulsivity/emotional
lability, and problems with self-concept. Reliability and validity for this scale are welldocumented [24]. Norms for all subscales are available with respect to age and gender.
The properties of the CAARS demonstrate its suitability for all three functions of a rating
scale in work with adults with ADHD in clinical practice. First, the CAARS can be used for
screening. The entire scale shows good discriminant validity [24] and also contains an ADHD
Index which the authors describe as producing the best discrimination between ADHD and nonADHD patients [25]. Short (26 items) and Screening (30 items) versions of the CAARS contain
this index and thus are suitable for use in screening for ADHD in adults. Second, the CAARS
would be useful as part of a comprehensive assessment of adult ADHD. DSM-IV symptom
counts can be derived (from items rated “Often” or above) and norms can be used to establish
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developmental deviance. Other-report forms can provide corroborating evidence of current
symptoms—a critical element of the assessment of ADHD symptoms in adults. (Note, however,
that the CAARS does not assess symptoms in childhood or age of onset.) Third, the full CAARS
or one of the shortened versions could be used to track treatment progress over time and the full
scales show good test-retest reliability (.88-.91.; Erhardt et al., 1999).
The CAARS suite of products is available from Multi-Health Systems and appears to be
the most comprehensive package of rating scale products currently available to a clinician
working with adults with ADHD. Hand-scoring and computer-scoring packages are available.
Computer-scoring software generates two types of detailed reports from the measure. The
CAARS scales would be and excellent addition to the assessment library of a clinician who often
provides comprehensive assessment and treatment of adults for ADHD with cost and time of
administration/scoring being perhaps the most prohibitive factors.
CONCLUSIONS
Although this chapter describes how rating scales are used in our research group at
Massachusetts General Hospital, a clinician wishing to assess ADHD in adults must collect
multiple types of data from multiple sources to address each of the criteria in DSM-IV and to rule
out alternative explanations for the patient’s presenting problems. Other authors [26][27] address
the complexities inherent in this process and readers should refer to these resources for a full
discussion of assessment issues in adult ADHD. Brief consideration of several issues in the
assessment of adult ADHD helps to define the role of rating scales in clinical practice.
First, the symptom criteria for the disorder as outlined in DSM-IV have been criticized as
not developmentally appropriate for capturing the expression of ADHD symptoms in adults and
symptom thresholds for diagnosis may be too stringent [28]. Items must reflect adult symptoms
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while keeping content consistent with research-based conceptualizations of the disorder. Second,
a patient’s symptoms must be in excess of those exhibited by individuals of similar
developmental level, requiring some ability to compare patient’s symptom severity with other
adults. Third, onset of symptoms and at least some impairment must occur in childhood,
highlighting the need for retrospective reporting and review of documentation. Fourth,
corroborating evidence of both current and past symptoms via other-report is essential to
accurate diagnosis, and the extent to which these sources of data converge is often variable
[29][30][31]. Finally, assessment of comorbid disorders is critical, given that adults with ADHD
report significantly more comorbid disorders than their non-ADHD counterparts [32]. The
clinician must rule out that other disorders account for symptoms and must assess the influence
of other disorders on impairment and their possible impact on treatment of ADHD. Because of
these complexities, expert clinicians emphasize that the assessment process must be
comprehensive and multi-method (Murphy & Gordon, 2006). Thus, rating scales are only one
element in a comprehensive assessment of adult ADHD.
In summary, assessment of ADHD in adults is a challenging process with a growing, but still
limited, base of empirically-derived knowledge. Rating scales based on DSM-IV symptoms
appear to be an efficient way to collect self-report data on current symptoms for use in screening,
as part of a comprehensive ADHD assessment, and in tracking treatment progress. The Adult
ADHD Self-Report Rating Scale [6] is a widely-available scale that can be used by busy
clinicians for screening or in tracking treatment progress. Several other scales are available based
on a clinician’s needs and resources, including the Current Symptoms Scale [5] and the Conners’
Adult ADHD Rating Scale [18]. Although the benefits of incorporating rating scales for adult
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ADHD into clinical practice certainly outweigh the costs, more research is needed on their
application in the three roles outlined in this chapter.
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